Kodiak Sciences Inc., a clinical stage biopharmaceutical company, focuses on the research and development of therapeutics aimed at addressing retinal diseases. Its lead product candidate, KSI-301, is an anti-vascular endothelial growth factor antibody biopolymer currently undergoing Phase IIb/III clinical studies for the treatment of wet age-related macular degeneration (AMD) and other conditions such as diabetic macular edema and non-proliferative diabetic retinopathy. The EBITDA ratio is 0.00 highlighting the company's operational efficiency. The company recorded an operating income of -$186,849,000.00 reflecting its earnings from core operations, while the operating income ratio is 0.00 indicating the company's operational profitability margin. Additionally, it incurred an interest expense of $0.00 reflecting its debt servicing obligations. The net total of other income and expenses is $10,642,000.00 which reflects non-core financial activities. Alongside KSI-301, Kodiak is advancing other preclinical stage product candidates, including KSI-501, a bispecific conjugate targeting retinal diseases with an inflammatory component, and KSI-601, which is a triplet inhibitor designed to treat dry AMD. Originally known as Oligasis, LLC, the company rebranded to Kodiak Sciences Inc. in September 2015 and was incorporated in 2009, with its headquarters based in Palo Alto, California. The stock is affordable at $4.49 making it an attractive option for budget-conscious investors. With a market capitalization of $236,908,115.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, the stock has a low average trading volume of 388,555.00 indicating lower market activity. Kodiak Sciences Inc. belongs to the Healthcare sector, driving innovation and growth in the biopharmaceutical field as it seeks to develop and commercialize promising treatments for retinal diseases.